About this trial

The goal of this clinical trial is to learn about radiofrequency ablation in patients with unresectable bile duct cancer who receive systemic chemotherapy and bile duct stenting. The main questions it aims to answer are:

* Does radiofrequency ablation of tumorous bile duct occlusion reduce risk of complications in these patients (eg stent dysfunction, delay of chemotherapy, infections etc)? * Is radiofrequency ablation safe in these patients? All participants will receive standard treatment with systemic chemotherapy and bile duct stenting. Researchers will compare two groups (one group will receive additional radiofrequency ablation, the other not).

Eligibility criteria

Qualifiers

Unresectable perihilar and/or ductal CCA with bile duct stenting and palliative systemic therapy as indicated by the local Multidisciplinary Team (MDT)

Written informed consent

Eastern Cooperative Oncology Group (ECOG) performance status 0-1

Age ≥18 years

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Intraductal biliary radiofrequency ablation

Treatment groups

130 Participants
are divided into 2 treatment groups

Locations

1
University Medical Center Hamburg-Eppendorf Hamburg Germany

Sponsors and collaborators

Universitätsklinikum Hamburg-Eppendorf

Lead sponsor